Evidence map›Paper›PMID 25405219›Full record

ReviewTheScientificWorldJournal2014

Hemifacial spasm and neurovascular compression.

Alex Y Lu, Jacky T Yeung, Jason L Gerrard, Elias M Michaelides, Raymond F Sekula, Ketan R Bulsara

Abstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Cyberknife radiosurgery for hemifacial spasm.Surgical neurology international · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Preliminary Report of Fully Endoscopic Microvascular Decompression.Journal of Korean Neurosurgical Society · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alex Y LuDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT 06520, USA.
Jacky T YeungDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT 06520, USA.
Jason L GerrardDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT 06520, USA.
Elias M MichaelidesSection of Otolaryngology, Yale School of Medicine, New Haven, CT 06520, USA.
Raymond F SekulaHamot Hospital, University of Pittsburgh Medical Center, Erie, PA 16507, USA.
Ketan R BulsaraDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT 06520, USA.

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
NCATS NIH HHS UL1 TR000142
6 · The paper itself

Abstract

Hemifacial spasm (HFS) is characterized by involuntary unilateral contractions of the muscles innervated by the ipsilateral facial nerve, usually starting around the eyes before progressing inferiorly to the cheek, mouth, and neck. Its prevalence is 9.8 per 100,000 persons with an average age of onset of 44 years. The accepted pathophysiology of HFS suggests that it is a disease process of the nerve root entry zone of the facial nerve. HFS can be divided into two types: primary and secondary. Primary HFS is triggered by vascular compression whereas secondary HFS comprises all other causes of facial nerve damage. Clinical examination and imaging modalities such as electromyography (EMG) and magnetic resonance imaging (MRI) are useful to differentiate HFS from other facial movement disorders and for intraoperative planning. The standard medical management for HFS is botulinum neurotoxin (BoNT) injections, which provides low-risk but limited symptomatic relief. The only curative treatment for HFS is microvascular decompression (MVD), a surgical intervention that provides lasting symptomatic relief by reducing compression of the facial nerve root. With a low rate of complications such as hearing loss, MVD remains the treatment of choice for HFS patients as intraoperative technique and monitoring continue to improve.

Indexed as

Decompression, SurgicalAdultAge of OnsetBotulinum Toxins, Type AElectromyographyFacial NerveFemaleHemifacial SpasmHumansMagnetic Resonance ImagingMaleMicrosurgeryMiddle AgedNerve Compression SyndromesNeuromuscular AgentsBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agents

Identifiers

PMID25405219
PMCPMC4227371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.